A Phase 1 interventional study of Mirikizumab Test and Mirikizumab Test in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-21.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is conducted to compare how much mirikizumab, in two different formulations, is absorbed into the bloodstream and how long the body takes to get rid of it, when given as an injection under the skin or into the veins. Side effects of the injection will be collected. Each participant will be in the study for about 18 weeks, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
250 mg mirikizumab test formulation given as a single injection SC in healthy participants
Biological: Mirikizumab Test
250 mg mirikizumab test formulation given as two injections given SC in healthy participants
Biological: Mirikizumab Test
250 mg mirikizumab test formulation given as an infusion into the vein in healthy participants
Biological: Mirikizumab Test
250 mg mirikizumab reference formulation given as three injections subcutaneous (SC) in healthy participants
Biological: Mirikizumab Reference
Administered SC
Also known as: LY3074828
Administered IV
Also known as: LY3074828
Administered SC
Also known as: LY3074828
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞]) of Mirikizumab
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC\[0-∞\]) of Mirikizumab
Time frame: 0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose
PK: Maximum Observed Concentration (Cmax) of Mirikizumab
PK: Maximum Observed Concentration (Cmax) of Mirikizumab
Time frame: 0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose
PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab
PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab
Time frame: 0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose
| Milestone | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) |
|---|---|---|---|---|
| Started | 17 | 16 | 17 | 17 |
| Received at least one dose of study drug | 17 | 16 | 17 | 17 |
| Completed | 17 | 16 | 17 | 16 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC\[0-∞\]) of Mirikizumab
| Microgram* Day/Milliliter(µg*day/mL) | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞]) of Mirikizumab | 215 ± 31 | 214 ± 55 | 293 ± 36 | 695 ± 22 |
PK: Maximum Observed Concentration (Cmax) of Mirikizumab
| Microgram/Milliliter (µg/mL) | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) |
|---|---|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Mirikizumab | 11.4 ± 34 | 11.2 ± 51 | 14.9 ± 32 | 90.0 ± 14 |
PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab
| Hour (h) | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) |
|---|---|---|---|---|
| PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab | 73.12 (72.45 to 145.82) | 73.41 (72.67 to 240.67) | 73.25 (72.22 to 145.30) | 2.00 (0.50 to 2.15) |
Collected over Up To 4 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mirikizumab Reference | 0/17 (0%) | 0/17 (0%) | 17/17 (100%) |
| Mirikizumab Test SC 2 | 0/16 (0%) | 0/16 (0%) | 15/16 (93.8%) |
| Mirikizumab Test SC 1 | 0/17 (0%) | 0/17 (0%) | 17/17 (100%) |
| Mirikizumab Test Intravenous (IV) | 0/17 (0%) | 0/17 (0%) | 15/17 (88.2%) |
| Event | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 17/17 | 15/16 | 17/17 | 0/17 |
| NasopharyngitisInfections and infestations | 5/17 | 2/16 | 1/17 | 7/17 |
| HeadacheNervous system disorders | 2/17 | 2/16 | 2/17 | 4/17 |
| Abdominal pain upperGastrointestinal disorders | 2/17 | 0/16 | 0/17 | 0/17 |
| DiarrhoeaGastrointestinal disorders | 1/17 | 1/16 | 2/17 | 0/17 |
| Injection site bruisingGeneral disorders | 2/17 | 0/16 | 0/17 | 0/17 |
| PalpitationsCardiac disorders | 0/17 | 1/16 | 0/17 | 0/17 |
| Ear painEar and labyrinth disorders | 0/17 | 1/16 | 0/17 | 0/17 |
| Abdominal discomfortGastrointestinal disorders | 0/17 | 1/16 | 0/17 | 0/17 |
| Abdominal distensionGastrointestinal disorders | 1/17 | 1/16 | 0/17 | 0/17 |
All randomized participants.
| Age, Continuous(years) | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) | Total |
|---|---|---|---|---|---|
| Mean | 44.7 ± 13.3 | 40.7 ± 18.0 | 52.1 ± 9.6 | 43.6 ± 14.9 | 45.4 ± 14.5 |
| Sex: Female, Male(Participants) | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) | Total |
|---|---|---|---|---|---|
| Female | 6 | 5 | 9 | 8 | 28 |
| Male | 11 | 11 | 8 | 9 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 2 | 2 |
| Not Hispanic or Latino | 17 | 16 | 17 | 15 | 65 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 1 | 3 |
| White | 17 | 13 | 17 | 16 | 63 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Mirikizumab Reference | Mirikizumab Test SC 2 | Mirikizumab Test SC 1 | Mirikizumab Test Intravenous (IV) | Total |
|---|---|---|---|---|---|
| United Kingdom | 17 | 16 | 17 | 17 | 67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in Apr 2018, 11 months.
Results were first posted in Feb 2024, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab